Analysed ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) News Sources
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
31-03-2026
yahoo.com
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3
02-04-2026
yahoo.com
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data
06-04-2026
yahoo.com
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
17-04-2026
yahoo.com
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
17-05-2026
yahoo.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02-07-2026
yahoo.com
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
03-08-2026
yahoo.com
What is the current price of ORIC PHARMACEUTICALS INC (ORIC:NASDAQ)?
The current price of ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) is $13.46.
ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) absolute price change since previous trading day?
The absolute price change of ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) since the previous trading day is $-0.74.
ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) percentage price change since previous trading day?
The percentage price change of ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) since the previous trading day is -5.2113%.
What is the most recent average sentiment score for ORIC PHARMACEUTICALS INC (ORIC:NASDAQ)?
The most recent average sentiment score for ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for ORIC PHARMACEUTICALS INC (ORIC:NASDAQ)?
The most recent sentiment for ORIC PHARMACEUTICALS INC (ORIC:NASDAQ) is .
SEC-8K** Filing Available For ORIC PHARMACEUTICALS INC (ORIC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.